09:12 AM EDT, 07/16/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Tuesday that Health Canada has approved its phase 2a dose confirmation study of tolimidone to treat type 1 diabetes.

The biopharmaceutical company said the study will measure C-peptide levels, a marker for insulin, and blood glucose marker HbA1c after three months compared with baseline and the number of hyperglycemic events in 12 patients initially.

Biodexa said it expects patient enrollment for the study to begin in Q2.

Shares of Biodexa were up more than 15% in recent premarket activity.

Price: 1.1200, Change: +0.15, Percent Change: +15.46